Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia?

References

• Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors. 2004;22:123–131.
   PubMed Web of Science ®Google Scholar
• Lu B, Martinowich K. Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp. 2008;289:119–129.
   PubMedGoogle Scholar
• Tejeda GS, Diaz-Guerra M. Integral characterization of defective BDNF/TrkB signalling in neurological and psychiatric disorders leads the way to new therapies. Int J Mol Sci. 2017;18:119.
   Web of Science ®Google Scholar
• Matsuoka Y, Nishi D, Tanima Y. Serum pro-BDNF/BDNF as a treatment biomarker for response to docosahexaenoic acid in traumatized people vulnerable to developing psychological distress: a randomized controlled trial. Transl Psychiatry. 2015;5:e596.
   PubMed Web of Science ®Google Scholar
• Phillips HS, Hains JM, Armanini M, et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron. 1991;7:695–702.
   PubMed Web of Science ®Google Scholar
• Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328:261–264.
   PubMed Web of Science ®Google Scholar
• Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93.
   PubMed Web of Science ®Google Scholar
• Makinen J, Miettunen J, Isohanni M, et al. Negative symptoms in schizophrenia: a review. Nord J Psychiatry. 2008;62:334–341.
   PubMed Web of Science ®Google Scholar
• Weinberger DR. The neurodevelopmental origins of schizophrenia in the penumbra of genomic medicine. World Psychiatry. 2017;16:225–226.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Kałużyńska O, Wysokiński A. BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Res. 2016;242:54–60.
   PubMed Web of Science ®Google Scholar
• Golden E, Emiliano A, Maudsley S, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS One. 2010;5:e10099.
   PubMed Web of Science ®Google Scholar
• Nurjono M, Tay YH, Lee J. The relationship between serum brain-derived neurotrophic factor (BDNF) and cardiometabolic indices in schizophrenia. Schizophr Res. 2014;157:244–248.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Vincenzi B, Andrea NV, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2:452–464.
   PubMed Web of Science ®Google Scholar
• Bent-Ennakhil N, Cecile-Perier M, Sobocki P, et al. Incidence of cardiovascular diseases and type-2-diabetes mellitus in patients with psychiatric disorders. Nord J Psychiatry. 2018;72:455–461.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Wu GY, et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology. 2008;33:2200–2205.
   PubMed Web of Science ®Google Scholar
• Bonaccorso S, Sodhi M, Li J, et al. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disord. 2015;17:528–535.
   PubMed Web of Science ®Google Scholar
• Zai GC, Zai CC, Chowdhury NI, et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:96–101.
   PubMed Web of Science ®Google Scholar
• Lepeta K, Kaczmarek L. Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia. Schizophr Bull. 2015;41:1003–1009.
   PubMed Web of Science ®Google Scholar
• Yamamori H, Hashimoto R, Ishima T, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. 2013;556:37–41.
   PubMed Web of Science ®Google Scholar
• Rybakowski JK. Matrix metalloproteinase-9 (MMP9)-a mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovasc Psychiatry Neurol. 2009;2009:904836.
   PubMedGoogle Scholar
• Bosy-Westphal A, Later W, Hitze B, et al. Accuracy of bioelectrical impedance consumer devices for measurement of body composition in comparison to whole body magnetic resonance imaging and dual X-ray absorptiometry. Obes Facts. 2008;1:319–324.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480.
   PubMed Web of Science ®Google Scholar
• Leucht S, Samara M, Heres S, et al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42:S90–S94.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Tan YL, et al. Gender difference in association of cognition with BDNF in chronic schizophrenia. Psychoneuroendocrinology. 2014;48:136–146.
   PubMed Web of Science ®Google Scholar
• Green MJ, Matheson SL, Shepherd A, et al. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16:960–972.
   PubMed Web of Science ®Google Scholar
• Devanarayanan S, Nandeesha H, Kattimani S, et al. Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study. Clin Chem Lab Med. 2016;54:447–452.
   PubMed Web of Science ®Google Scholar
• Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010;5:e9166.
   PubMed Web of Science ®Google Scholar
• Lee J, Nurjono M, Lee TS. Levels of serum brain-derived neurotrophic factor in schizophrenia. J Nerv Ment Dis. 2016;204:636–639.
   PubMed Web of Science ®Google Scholar
• Skibinska M, Kapelski P, Rajewska-Rager A, et al. Elevated brain-derived neurotrophic factor (BDNF) serum levels in an acute episode of schizophrenia in polish women: correlation with clinical and metabolic parameters. Psychiatry Res. 2019;271:89–95.
   PubMed Web of Science ®Google Scholar
• Niitsu T, Ishima T, Yoshida T, et al. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2014;215:268–273.
   PubMed Web of Science ®Google Scholar
• Ali FT, Abd El-Azeem EM, Hamed MA, et al. Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res. 2017;188:98–109.
   PubMed Web of Science ®Google Scholar
• Derosa G, Ferrari I, D'Angelo A, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium. 2008;15:219–224.
   PubMed Web of Science ®Google Scholar
• Goncalves FM, Jacob-Ferreira AL, Gomes VA, et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta. 2009;403:173–177.
   PubMed Web of Science ®Google Scholar
• Roberts CK, Won D, Pruthi S, et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol (1985). 2006;100:1657–1665.
   PubMed Web of Science ®Google Scholar
• Yang F, Wang K, Du X, et al. Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia. Psychopharmacology (Berl). 2018;236:735–762.
   Web of Science ®Google Scholar
• Lin CC, Hung YY, Tsai MC, et al. Increased serum brain-derived neurotrophic factor in male schizophrenic patients with metabolic syndrome. Medicine (Baltimore). 2017;96:e7089.
   PubMed Web of Science ®Google Scholar
• Castren E, Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry. 2017;22:1085–1095.
   PubMed Web of Science ®Google Scholar
• Chen CC, Huang TL. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res. 2011;189:327.
   PubMed Web of Science ®Google Scholar
• Rizos EN, Papadopoulou A, Laskos E, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2010;11:251–255.
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol Clin Exp. 2012;27:33–38.
   PubMed Web of Science ®Google Scholar